Iain C Macdougall

Summary

Affiliation: King's College Hospital
Country: UK

Publications

  1. ncbi Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Clin J Am Soc Nephrol 1:1211-5. 2006
  2. ncbi Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks
    Iain C Macdougall
    King s College Hospital, Renal Unit, East Dulwich Grove, London SE5 9RS, UK
    Nephrol Dial Transplant 20:iv9-15. 2005
  3. ncbi Pharmacology of darbepoetin alfa
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Nephrol Dial Transplant 22:iv2-iv9. 2007
  4. ncbi Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial
    Iain C Macdougall
    The Renal Unit, King s College Hospital, Denmark Hill, London SE5 9RS, UK
    Nephrol Dial Transplant 22:784-93. 2007
  5. ncbi Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Am J Kidney Dis 46:283-9. 2005
  6. ncbi Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London SE5 9RS, UK
    Lancet 368:947-53. 2006
  7. ncbi Recent advances in erythropoietic agents in renal anemia
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Semin Nephrol 26:313-8. 2006
  8. ncbi CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, Denmark Hill, London SE5 9RS, UK
    Curr Hematol Rep 4:436-40. 2005
  9. ncbi Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure
    Angela Cooper
    Department of Renal Medicine, GKT School of Medicine, King s College Hospital, London, United Kingdom
    J Am Soc Nephrol 15:1877-82. 2004
  10. ncbi Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients?
    Iain C Macdougall
    Renal Unit, King s College Hospital, East Dulwich Grove, London SE22 8PT, UK
    Nephrol Dial Transplant 19:V73-78. 2004

Detail Information

Publications70

  1. ncbi Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Clin J Am Soc Nephrol 1:1211-5. 2006
    ..C.E.R.A. has a prolonged and comparable half-life after intravenous or subcutaneous injection, suggesting that extended administration intervals may be feasible in patients with CKD...
  2. ncbi Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks
    Iain C Macdougall
    King s College Hospital, Renal Unit, East Dulwich Grove, London SE5 9RS, UK
    Nephrol Dial Transplant 20:iv9-15. 2005
    ..However, therapeutic approaches for this serious immunological reaction to recombinant ESAs remain investigative...
  3. ncbi Pharmacology of darbepoetin alfa
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Nephrol Dial Transplant 22:iv2-iv9. 2007
    ..More rigorous studies will be needed to confirm these findings...
  4. ncbi Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial
    Iain C Macdougall
    The Renal Unit, King s College Hospital, Denmark Hill, London SE5 9RS, UK
    Nephrol Dial Transplant 22:784-93. 2007
    ..This multicentre, open-label prospective, randomized, comparative-group study evaluated the effects of maintaining haemoglobin (Hb) in pre-dialysis chronic kidney disease (CKD) patients...
  5. ncbi Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Am J Kidney Dis 46:283-9. 2005
    ..Traditionally, this has been administered as an infusion over 1 or more hours, which requires the use of intravenous fluids and administration tubing, along with extra demands on patient and nursing time...
  6. ncbi Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London SE5 9RS, UK
    Lancet 368:947-53. 2006
    ..We review these new therapeutic strategies, and discuss at what stage some of the newer products are in relation to their clinical development programme...
  7. ncbi Recent advances in erythropoietic agents in renal anemia
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Semin Nephrol 26:313-8. 2006
    ..Other strategies for stimulating erythropoiesis, briefly described in this review, are at an earlier stage of development. This is an exciting and rapidly developing area of scientific and translational research...
  8. ncbi CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, Denmark Hill, London SE5 9RS, UK
    Curr Hematol Rep 4:436-40. 2005
    ..CERA may also have different receptor binding characteristics and pharmacology from other erythropoietic agents; these characteristics are the subject of ongoing investigation. CERA is currently in phase III clinical trials...
  9. ncbi Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure
    Angela Cooper
    Department of Renal Medicine, GKT School of Medicine, King s College Hospital, London, United Kingdom
    J Am Soc Nephrol 15:1877-82. 2004
    ..This may occur due to inhibition of proinflammatory cytokine production, which could interfere with the effectiveness of rh-Epo...
  10. ncbi Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients?
    Iain C Macdougall
    Renal Unit, King s College Hospital, East Dulwich Grove, London SE22 8PT, UK
    Nephrol Dial Transplant 19:V73-78. 2004
    ..Ongoing studies will investigate further the use of pentoxifylline in erythropoietin resistance...
  11. ncbi Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Nephrol Dial Transplant 19:2901-5. 2004
  12. ncbi A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London
    N Engl J Med 361:1848-55. 2009
    ..We investigated whether a novel, synthetic, peptide-based erythropoietin-receptor agonist (Hematide, Affymax) can stimulate erythropoiesis in patients with anemia that is caused by antierythropoietin antibodies...
  13. doi Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis
    Iain C Macdougall
    Renal Unit, King s College Hospital, London, United Kingdom
    N Engl J Med 368:320-32. 2013
    ..We evaluated the safety and efficacy of peginesatide, as compared with another ESA, darbepoetin, in 983 such patients who were not undergoing dialysis...
  14. pmc Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients
    Iain C Macdougall
    Renal Unit, King s College Hospital, London, United Kingdom
    Clin J Am Soc Nephrol 6:2579-86. 2011
    ..We report the first assessment of its efficacy and safety in correcting renal anemia in a population of 139 nondialysis chronic kidney disease patients...
  15. ncbi Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy
    Angela C Cooper
    Department of Renal Medicine, GKT School of Medicine, King s College Hospital, Bessemer Road, London SE5 9PJ, UK
    J Am Soc Nephrol 14:1776-84. 2003
    ..In the absence of any other cause (such as iron deficiency), the overproduction of cytokines may account for hyporesponsiveness to erythropoietic therapy in patients with renal failure...
  16. ncbi Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Nephrol Dial Transplant 18:576-81. 2003
    ..The optimal starting dose and frequency of administration of darbepoetin alfa were investigated for treating renal anaemia in dialysis patients...
  17. ncbi How to optimise anaemia therapy in peritoneal dialysis patients
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Contrib Nephrol 150:202-13. 2006
    ..This article aims to explore some of these issues in greater detail so that patients on peritoneal dialysis can derive the greatest benefits from correction of anaemia and maintenance of an adequate haemoglobin...
  18. ncbi Erythropoietin and renal failure
    Iain C Macdougall
    Renal Unit, King s College Hospital, East Dulwich Grove, London SE22 8PT, UK
    Curr Hematol Rep 2:459-64. 2003
    ..This review addresses these topics and focuses largely on the publications relevant to these areas of clinical anemia management...
  19. pmc C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, Bessemer Road, London, SE5 9RS, UK
    Clin J Am Soc Nephrol 3:337-47. 2008
    ..This study examined the efficacy of C.E.R.A., a continuous erythropoietin receptor activator, for correcting anemia in patients who had chronic kidney disease (CKD) and were not on dialysis...
  20. ncbi Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines
    Iain C Macdougall
    Departments of Renal Medicine and Immunology, King s College Hospital, London, UK
    Nephrol Dial Transplant 17:39-43. 2002
    ..Strategies utilizing anti-cytokine therapy may prove to be a useful adjuvant in optimizing the response to rHuEPO therapy...
  21. ncbi Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production
    Angela C Cooper
    Department of Immunology, Guy s, King s and St Thomas School of Medicine, King s College Hospital, London, UK
    Nephrol Dial Transplant 18:133-40. 2003
    ..However, 5-10% of such patients do not respond adequately and an important contributory factor to this is chronic inflammation...
  22. ncbi Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?
    Iain C Macdougall
    Renal Unit, King s College Hospital, East Dulwich Grove, London SE22 8PT, UK
    Nephrol Dial Transplant 20:viii18-21. 2005
    ..This article provides an overview of the recent history and growing understanding of ESA-associated PRCA together with current approaches to the management of this rare side effect of an otherwise valuable therapy...
  23. ncbi Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up
    Helen L MacLaughlin
    Department of Nutrition and Dietetics, King s College Hospital, London SE5 9RS, UK
    Am J Kidney Dis 55:69-76. 2010
    ..Obesity increases the comorbidity-adjusted relative risk of developing end-stage renal disease. Body mass index (BMI) > 30 kg/m(2) was a contraindication for transplant in our renal unit until 2008...
  24. ncbi Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another
    Iain C Macdougall
    Renal Unit, King s College Hospital, East Dulwich Grove, London SE22 8PT, UK
    Curr Med Res Opin 20:83-6. 2004
    ..To compare rates of pure red cell aplasia (PRCA) over time in patients with chronic renal failure treated with subcutaneous injections of two brands of epoetin alfa (either Eprex or Epogen) or epoetin beta (NeoRecormon)...
  25. ncbi Dialysis facility ownership and epoetin dosing in hemodialysis patients: a view from Europe
    Iain C Macdougall
    King s College Hospital, London, United Kingdom
    Am J Kidney Dis 50:358-61. 2007
  26. ncbi Epoetin-induced pure red cell aplasia: diagnosis and treatment
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Curr Opin Nephrol Hypertens 16:585-8. 2007
    ..The incidence of this adverse effect peaked in 2002, but new cases still appear sporadically. The aim of this review is to discuss the latest opinions regarding the detection and management of this condition...
  27. ncbi Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Nephrol Dial Transplant 17:66-70. 2002
    ..A small number of studies have supported the once-weekly use of rHuEPO. All clinical trials so far conducted on darbepoetin alfa have demonstrated success with once-weekly and once every other week dosing...
  28. doi Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, United Kingdom
    Adv Chronic Kidney Dis 16:117-30. 2009
    ..In conclusion, the development of effective therapies for the treatment of anemia has been a highly active field, both scientifically and economically, over the last two decades...
  29. ncbi Compliance with a structured weight loss program is associated with reduced systolic blood pressure in obese patients with chronic kidney disease
    Helen L MacLaughlin
    Diabetes and Nutritional Sciences Division, King s College London, London, UK
    Am J Hypertens 25:1024-9. 2012
    ..This study examined the effectiveness of a weight management program (WMP), and sought to determine factors associated with successful weight loss in obese patients with chronic kidney disease (CKD)...
  30. doi Serum hemojuvelin and hepcidin levels in chronic kidney disease
    Adam Rumjon
    Department of Renal Medicine, King s College Hospital, London, UK
    Am J Nephrol 35:295-304. 2012
    ..Recently, an immunoassay has been developed to measure circulating levels of soluble HJV (sHJV). The aim of this study was to measure serum hepcidin and sHJV levels in a chronic kidney disease (CKD) population...
  31. doi New anemia therapies: translating novel strategies from bench to bedside
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, United Kingdom
    Am J Kidney Dis 59:444-51. 2012
    ....
  32. doi Iron supplementation in nephrology and oncology: what do we have in common?
    Iain C Macdougall
    Renal Unit, King s College Hospital, London SE5 9RS, United Kingdom
    Oncologist 16:25-34. 2011
    ..v. iron are reassuring, the long-term safety of parenteral iron is not established in well-designed adequately powered randomized controlled trials...
  33. doi Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up
    Iain C Macdougall
    Renal Unit, King s College Hospital, London, UK
    Nephrol Dial Transplant 25:914-9. 2010
    ..This has arisen from the paradoxical conclusions obtained from large retrospective or epidemiological studies versus interventional randomized controlled trials...
  34. ncbi Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, Bessemer Road, London SE5 9RS, UK
    Curr Med Res Opin 26:473-82. 2010
    ..The management of iron-deficiency anaemia in patients with non-dialysis chronic kidney disease (ND-CKD) remains controversial, particularly regarding the use of oral versus intravenous iron supplementation...
  35. ncbi Novel erythropoiesis-stimulating agents: a new era in anemia management
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, United Kingdom
    Clin J Am Soc Nephrol 3:200-7. 2008
    ..This article reviews the latest progress with these novel erythropoietic agents in this new era in anemia management...
  36. ncbi Erythropoietin treatment in the neuropsychiatric porphyrias
    Andrea S Winkler
    Department of Medicine, King s College Hospital, London, UK
    Clin Chim Acta 338:61-6. 2003
    ..We were also able to demonstrate that treatment with erythropoietin in non-porphyric patients (mainly diabetic patients with autonomic neuropathy) significantly reduced urinary delta-aminolaevulinic acid levels...
  37. doi Obesity does not influence hepcidin and hemojuvelin levels in hemodialysis patients
    Pantelis A Sarafidis
    Department of Renal Medicine, King s College London, London, United Kingdom
    Nephron Clin Pract 124:159-66. 2013
    ..Clinical studies have shown increased levels of hepcidin causing functional iron deficiency in obese individuals. This study examined whether obesity contributes to increased hepcidin and hemojuvelin levels in adult hemodialysis patients...
  38. doi An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic
    Paul D Wilson
    Department of Renal Medicine, King s College Hospital, London, UK
    J Med Econ 16:108-14. 2013
    ..This study investigated the potential impact on patient experience and service costs by switching from IS to ferric carboxymaltose (FCM)...
  39. ncbi Use of intravenous iron supplementation in chronic kidney disease: an update
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Iran J Kidney Dis 7:9-22. 2013
    ..In conclusion, we now have the ability to achieve iron replenishment rapidly and conveniently in dialysis-dependent and nondialysis-dependent CKD patients without compromising safety...
  40. doi Evaluation of a pragmatic exercise rehabilitation programme in chronic kidney disease
    Sharlene A Greenwood
    King s College Hospital, London, UK
    Nephrol Dial Transplant 27:iii126-34. 2012
    ..This study included 263 patients, consecutively referred over a 4-year period, to a pragmatic 12-week renal rehabilitation (RR) programme delivered within a National Health Service (NHS)...
  41. ncbi Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights
    Iain C Macdougall
    Renal Unit, King s College Hospital, London, UK
    Kidney Int 81:727-32. 2012
    ..This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy...
  42. doi Evolution of iv iron compounds over the last century
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    J Ren Care 35:8-13. 2009
    ..However, the long-term safety of the newer IV iron preparations is not yet established...
  43. doi Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres
    Alison Roche
    King s College Hospital, London, UK
    Curr Med Res Opin 25:2971-6. 2009
    ..Monthly Hb values were obtained over a 12-month period. The frequency, duration, amplitude and direction of Hb fluctuations (Hb outside the range 11-12 g/dl in the Australian data-set and 11-12.5 g/dl in the UK data-set) were evaluated...
  44. ncbi Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia
    Iain C Macdougall
    King s College Hospital, Renal Unit, Denmark Hill, London SE5 9RS, UK
    Curr Opin Investig Drugs 9:1034-47. 2008
    ..Hematide is a synthetic peptide-based erythropoiesis-stimulating agent that is being developed by Affymax Inc and Takeda Pharmaceutical Co Ltd. Hematide is undergoing phase III clinical trials for anemia...
  45. ncbi Current status of the measurement of blood hepcidin levels in chronic kidney disease
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Clin J Am Soc Nephrol 5:1681-9. 2010
    ..Thus, although mass spectrometry is more accurate, it is less practical for routine clinical use at the present time...
  46. ncbi CREATE: new strategies for early anaemia management in renal insufficiency
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Nephrol Dial Transplant 18:ii13-6. 2003
    ..The CREATE trial is anticipated to provide important new data that could have an impact on new strategies for management of patients with moderate anaemia and CKD not yet requiring renal replacement therapy...
  47. ncbi Over 5 years of darbepoetin alfa: two case histories
    Alison J Roche
    Renal Unit, King s College Hospital Dulwich, East Dulwich Grove, London, UK
    Expert Opin Pharmacother 5:951-4. 2004
    ..Clinical trials with darbepoetin alfa began in 1997 and this brief article reports on two patients whose long-term anaemia management has been simplified by its use...
  48. ncbi Intra-dialytic exercise training: a pragmatic approach
    Sharlene A Greenwood
    Department of Renal Medicine, King s College Hospital, London, UK
    J Ren Care 40:219-26. 2014
    ..This continuing education paper outlines the skills and knowledge required to plan, implement and evaluate a pragmatic approach to intra-dialytic exercise training...
  49. doi Laparoscopic sleeve gastrectomy is a novel and effective treatment for obesity in patients with chronic kidney disease
    Helen L MacLaughlin
    Diabetes and Nutritional Sciences, School of Medicine, King s College London, London, UK
    Obes Surg 22:119-23. 2012
    ..Our preliminary evidence suggests that LSG is an effective treatment for obesity in patients with CKD. However, there may be additional risk associated with the procedure in patients with CKD, requiring further study...
  50. ncbi The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients
    Althea Mahon
    Department of Renal Medicine, King s College Hospital, London, UK
    Am J Kidney Dis 45:381-7. 2005
    ..The aim of this study was to evaluate the safety and effectiveness of sildenafil in male peritoneal dialysis patients with erectile dysfunction...
  51. pmc The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, Denmark Hill, London, UK
    Nephrol Dial Transplant 29:843-50. 2014
    ....
  52. doi How important is transfusion avoidance in 2013?
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London SE5 9RS, UK
    Nephrol Dial Transplant 28:1092-9. 2013
    ..The aim of this review is to reassess how important transfusion avoidance is in 2013, and whether we should still have the same concerns about HLA sensitization that we had 20 years ago...
  53. ncbi A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease
    Sharlene A Cook
    Department of Physiotherapy, King s College Hospital, London, UK
    Nephrol Dial Transplant 23:263-8. 2008
    ....
  54. ncbi The inflammatory response and epoetin sensitivity
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Nephrol Dial Transplant 17:48-52. 2002
    ..05). Further work in this area is required to confirm or contest the hypothesis that epoetin resistance is due to enhanced levels of immune activation...
  55. pmc Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London SE5 9RS, UK
    Eur J Heart Fail 14:882-6. 2012
    ..It is to be hoped that these important clinical trials are conducted, to permit a more subtle characterization of the patient's pathological condition and interventional requirements...
  56. ncbi Serum erythropoietin levels may be inappropriately low in the acute neuropsychiatric porphyrias
    Andrea S Winkler
    Department of Medicine, King s College Hospital, Denmark Hill, SE5 9RS, London, UK
    Clin Chim Acta 317:93-100. 2002
    ..Renal damage and sympathetic failure may both cause erythropoietin (EPO) deficiency. In this study, we have investigated serum erythropoietin levels and autonomic function in patients with acute porphyria in clinical remission...
  57. ncbi Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study
    David Verhelst
    Department of Nephrology, Tenon Hospital, Assistance Publique Hopitaux de Paris, and Pierre and Marie Curie University, Paris, France
    Lancet 363:1768-71. 2004
    ..We aimed to collate clinical and pathological features in patients unequivocally shown to have erythropoietin-induced pure red cell aplasia...
  58. ncbi Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?
    Francesco Locatelli
    Nephrol Dial Transplant 19:288-93. 2004
  59. ncbi Predialysis Survey on Anemia Management: patient referral
    Walter H Horl
    Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin III, Wien, Austria
    Am J Kidney Dis 41:49-61. 2003
    ..In this presentation, we focus on demographic data and patient referral practices of patients who enter kidney centers...
  60. ncbi PRE-dialysis survey on anaemia management
    Fernando Valderrabano
    Servicio Nefrologia, Hospital Gregorio Maranon, Madrid, Spain
    Nephrol Dial Transplant 18:89-100. 2003
    ..The PRE-dialysis survey on anaemia management (PRESAM) was designed to assess the care given to pre-dialysis patients in the 12 months before haemodialysis or peritoneal dialysis, with emphasis on anaemia management...
  61. ncbi Once-weekly erythropoietic therapy: is there a difference between the available preparations?
    Iain C Macdougall
    Nephrol Dial Transplant 17:2047-51. 2002
  62. ncbi Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors
    Nilesh Shah
    Department of Renal Medicine and Transplantation, Guy s Hospital, London, United Kingdom
    Transplantation 81:1112-8. 2006
    ..The purpose of this study was to investigate a large posttransplant population from 3 centres in the UK to elucidate the point prevalence of PTA, its determinants and the use of erythropoiesis stimulating agents (ESA) in these patients...
  63. ncbi Erythropoiesis-stimulating agent hyporesponsiveness
    David W Johnson
    Department of Renal Medicine, University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia
    Nephrology (Carlton) 12:321-30. 2007
    ..A practical algorithm for approaching the investigation and management of patients with ESA hyporesponsiveness is also provided...
  64. doi Renal anemia: comparing current Eastern and Western European management practice (ORAMA)
    Andrzej Wiecek
    Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Francuska, Poland
    Ren Fail 30:267-76. 2008
    ..Anemia management in patients with chronic kidney disease shows considerable regional differences across Europe, and target attainment remains suboptimal in many European nephrology centers after the revised 2004 guidelines...
  65. ncbi Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    Tilman B Drueke
    Inserm Unité 507 and Assistance Publique Hôpitaux de Paris, Necker Hospital, Division of Nephrology, Paris, France
    N Engl J Med 355:2071-84. 2006
    ..Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established...
  66. ncbi Rapidly progressive renal failure associated with successful pharmacotherapy for obesity
    Helen MacLaughlin
    Nephrol Dial Transplant 22:2403-5; author reply 2405. 2007
  67. ncbi ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data
    F Locatelli
    Department of Nephrology and Dialysis, A Manzoni Hospital, Lecco Italy
    J Nephrol 21:592-603. 2008
    ..The Optimal Renal Anaemia Management Assessment (ORAMA) is the first European study investigating the impact of adherence to the 2004 revised European Best Practice Guidelines (EBPG) and its impact on patient outcomes...
  68. ncbi Once-weekly erythropoietic therapy: is there a difference between the available preparations?
    Iain C Macdougall
    Nephrol Dial Transplant 19:1940. 2004
  69. ncbi Latest US KDOQI Anaemia Guidelines update--what are the implications for Europe?
    Iain C Macdougall
    Nephrol Dial Transplant 22:2738-42. 2007
  70. ncbi Iron and the anaemia of chronic disease: a review and strategic recommendations
    Ivor Cavill
    Medical School, Cardiff University, UK
    Curr Med Res Opin 22:731-7. 2006
    ..A focused literature search was conducted after key issues had been identified. A series of recommendations was agreed, backed, wherever possible, by published evidence which is included in the annotations...